Alberta slams federal rollout of COVID-19 vaccine as positivity rate sits at 3.9% In March of last year, Lewis says Entos decided to change direction.
The company had been working on cancer treatments and vaccines but when the COVID-19 pandemic hit, Entos focused on developing a vaccine.They had the people and the know-how.
What they didn’t have was a way to actually make the vaccine.Lewis estimated Entos would need about $50 million to develop the company’s manufacturing capacity.The company has put profits and its own money towards that sum.Officials also asked the federal government for grants and received some money.